The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up
Abstract
PURPOSE: To evaluate the long-term results of high-dose therapy (HDT) in follicular lymphoma, with specific emphasis on the prognostic significance of polymerase chain reaction (PCR)–detectable Bcl-2/IgH rearrangements. PATIENTS AND METHODS: Between June 1985 and October 1995, 99 patients with follicular lymphoma received HDT as consolidation of second or subsequent remission. Bone marrow was treated in vitro with anti–B-cell antibodies and complement. RESULTS: Sixty-five patients remained alive, 49 treatment-failure free, with a median follow-up of 5.5 years (range, 1.5 to 12.5 years). Four “early” and 10 “late” deaths occurred from treatment-related causes; seven of the latter were due to secondary myelodysplasia (s-MDS) or secondary acute myeloblastic leukemia. Overall, 12 (12%) of the 99 patients developed s-MDS or acute myeloblastic leukemia. Kaplan-Meier estimates of freedom from recurrence (FFR) and survival rates at 5 years were 63% (95% confidence interval [CI], 52% to 72%) and 69% (95% CI, 58% to 78%), respectively. For all 99 patients, in multivariate analysis, absence of the Bcl-2/IgH rearrangement at the time of diagnosis (hazards ratio [HR], 0.39; P = .04) and three or fewer treatment episodes before HDT (HR, 0.03; P = .001) were significant prognostic factors for improved survival. For patients bearing Bcl-2/IgH rearrangements, in univariate and multivariate analyses, absence of a PCR-detectable Bcl-2/IgH rearrangement during follow-up was associated with a significantly lower risk of recurrence (adjusted HR, 0.13; P < .001) and death (HR, 0.25; P = .02), whereas the PCR status of the reinfused bone marrow did not correlate with outcome. CONCLUSION: Prolonged FFR can be achieved in patients with follicular lymphoma after HDT, but as yet there is no survival advantage compared with conventional treatment. These results confirm that elimination of cells bearing the Bcl-2/IgH rearrangement is highly desirable and should be attempted. The incidence of s-MDS is of increasing concern in this setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support
Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310213291702 · Cited by 644
Cited by
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 580
Montoto, S., Davies, A. J., Matthews, J., Calaminici, M., Norton, A. J., Amess, J., Vinnicombe, S., Waters, R., Rohatiner, A. Z. S., & Lister, T. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3260 · Cited by 397
Self-citationNon-Hodgkin Lymphoma: Diagnosis and Treatment
Ansell, S. M., & Armitage, J. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1087 · Cited by 356
Metadata
- Authors
- Apostolidis, J., Gupta, R. K., Grenzelias, D., Johnson, P. W. M., Pappa, V. I., Summers, K. E., Salam, A., Adams, K., Norton, A. J., Amess, J. A. L., Matthews, J., Bradburn, M., Lister, T. A., & Rohatiner, A. Z. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-02-01
- Volume
- 18
- Issue
- 3
- Pages
- 527-527
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2249107533
- Cited by
- 181
- References
- 2
- FWCI
- 12.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up. https://app.cochat.ai/papers/10.1200/jco.2000.18.3.527
- The paper
- Apostolidis, J., Gupta, R. K., Grenzelias, D., Johnson, P. W. M., Pappa, V. I., Summers, K. E., Salam, A., Adams, K., Norton, A. J., Amess, J. A. L., Matthews, J., Bradburn, M., Lister, T. A., & Rohatiner, A. Z. S. (2000). High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.3.527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.